These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26277033)

  • 1. Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder.
    Coccaro EF; Lee R; Breen EC; Irwin MR
    Psychiatry Res; 2015 Oct; 229(3):844-9. PubMed ID: 26277033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder.
    Coccaro EF; Lee RJ; Kavoussi RJ
    J Clin Psychiatry; 2009 Apr; 70(5):653-62. PubMed ID: 19389333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.
    Hollander E; Tracy KA; Swann AC; Coccaro EF; McElroy SL; Wozniak P; Sommerville KW; Nemeroff CB
    Neuropsychopharmacology; 2003 Jun; 28(6):1186-97. PubMed ID: 12700713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.
    Kavoussi RJ; Coccaro EF
    J Clin Psychiatry; 1998 Dec; 59(12):676-80. PubMed ID: 9921702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s).
    Barzman DH; DelBello MP; Adler CM; Stanford KE; Strakowski SM
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):665-70. PubMed ID: 17201610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impulsive aggression with irritability and responsive to divalproex: a pediatric bipolar spectrum disorder phenotype?
    Barzman DH; McConville BJ; Masterson B; McElroy S; Sethuraman G; Moore K; Kahwaty AM; Nelson D
    J Affect Disord; 2005 Nov; 88(3):279-85. PubMed ID: 16169087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma and cerebrospinal fluid inflammatory markers and human aggression.
    Coccaro EF; Lee R; Breen EC; Irwin MR
    Neuropsychopharmacology; 2023 Jun; 48(7):1060-1066. PubMed ID: 36804488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of impulse control disorders: A systematic review.
    Tahir T; Wong MM; Maaz M; Naufal R; Tahir R; Naidoo Y
    Psychiatry Res; 2022 May; 311():114499. PubMed ID: 35305343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study.
    George DT; Phillips MJ; Lifshitz M; Lionetti TA; Spero DE; Ghassemzedeh N; Doty L; Umhau JC; Rawlings RR
    J Clin Psychiatry; 2011 Jan; 72(1):60-5. PubMed ID: 20673556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.
    Anagnostou E; Esposito K; Soorya L; Chaplin W; Wasserman S; Hollander E
    J Clin Psychopharmacol; 2006 Aug; 26(4):444-6. PubMed ID: 16855475
    [No Abstract]   [Full Text] [Related]  

  • 11. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.
    Coccaro EF; Kavoussi RJ
    Arch Gen Psychiatry; 1997 Dec; 54(12):1081-8. PubMed ID: 9400343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design.
    Donovan SJ; Stewart JW; Nunes EV; Quitkin FM; Parides M; Daniel W; Susser E; Klein DF
    Am J Psychiatry; 2000 May; 157(5):818-20. PubMed ID: 10784478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label trial of divalproex extended-release in the treatment of borderline personality disorder.
    Simeon D; Baker B; Chaplin W; Braun A; Hollander E
    CNS Spectr; 2007 Jun; 12(6):439-43. PubMed ID: 17545954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salivary cortisol awakening levels are reduced in human subjects with intermittent explosive disorder compared with controls.
    Meruelo AD; Timmins MA; Irwin MR; Coccaro EF
    Psychoneuroendocrinology; 2023 May; 151():106070. PubMed ID: 36863129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated Plasma Oxidative Stress Markers in Individuals With Intermittent Explosive Disorder and Correlation With Aggression in Humans.
    Coccaro EF; Lee R; Gozal D
    Biol Psychiatry; 2016 Jan; 79(2):127-35. PubMed ID: 24582164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial.
    Mattes JA
    J Clin Psychiatry; 2008 Feb; 69(2):310-5. PubMed ID: 18232724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
    Hollander E; Chaplin W; Soorya L; Wasserman S; Novotny S; Rusoff J; Feirsen N; Pepa L; Anagnostou E
    Neuropsychopharmacology; 2010 Mar; 35(4):990-8. PubMed ID: 20010551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
    Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
    Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Overt Aggression Scale Modified (OAS-M) for clinical trials targeting impulsive aggression and intermittent explosive disorder: Validity, reliability, and correlates.
    Coccaro EF
    J Psychiatr Res; 2020 May; 124():50-57. PubMed ID: 32114032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comorbid intermittent explosive disorder and posttraumatic stress disorder: Clinical correlates and relationship to suicidal behavior.
    Fanning JR; Lee R; Coccaro EF
    Compr Psychiatry; 2016 Oct; 70():125-33. PubMed ID: 27624432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.